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Background-—Women with ST-segment–elevation myocardial infarction (STEMI) have higher mortality rates than men. We
investigated whether sex-related differences in timely access to care among STEMI patients may be a factor associated with
excess risk of early mortality in women.
Methods and Results-—We identified 6022 STEMI patients who had information on time of symptom onset to time of hospital
presentation at 41 hospitals participating in the ISACS-TC (International Survey of Acute Coronary Syndromes in Transitional
Countries) registry (NCT01218776) from October 2010 through April 2016. Patients were stratified into time-delay cohorts. We
estimated the 30-day risk of all-cause mortality in each cohort. Despite similar delays in seeking care, the overall time from
symptom onset to hospital presentation was longer for women than men (median: 270 minutes [range: 130–776] versus
240 minutes [range: 120–600]). After adjustment for baseline variables, female sex was independently associated with greater risk
of 30-day mortality (odds ratio: 1.58; 95% confidence interval, 1.27–1.97). Sex differences in mortality following STEMI were no
longer observed for patients having delays from symptom onset to hospital presentation of ≤1 hour (odds ratio: 0.77; 95%
confidence interval, 0.29–2.02).
Conclusions-—Sex difference in mortality following STEMI persists and appears to be driven by prehospital delays in hospital
presentation. Women appear to be more vulnerable to prolonged untreated ischemia.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01218776. ( J Am Heart Assoc. 2017;6:
e005968. DOI: 10.1161/JAHA.117.005968.)
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C ontroversies abound when examining sex differences inmortality following acute ST-segment–elevation myocar-
dial infarction (STEMI).1,2 Some studies point to a disadvan-
tage for women in the setting of STEMI.3,4 Others show
similar outcome profiles for women and men.5 Most of these
studies, however, focused only on clinical covariates, which
should be viewed cautiously, remembering that therapeutic
interventions have a large impact on outcomes.6 Indeed,
when rates of coronary revascularization and delays in
revascularization differ between men and women, the value
of sex as a prognostic factor may be under- or overestimated
by analyses that include patients with such marked differ-
ences in treatment. Careful adjustment for differing use of
reperfusion therapies and time to treatment is important
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because women are less likely to receive timely in-hospital
reperfusion therapy.
The timeliness of reperfusion therapy in STEMI depends
largely on patients’ health awareness, ability to recognize the
early signs or symptoms, and access to health services and on
hospital quality performance, specifically door-to-balloon and
door-to needle times. Several studies have focused on the
associations between door-to-balloon and door-to needle
delays and outcomes.7,8 Fewer studies have investigated the
associations between overall treatment delay and mortality.9
No studies have evaluated the effect of treatment delays on sex
differences in early cardiac mortality. This study investigated
whether sex-based differences in access to care for patients
with STEMI were associated with differences in outcomes.
Methods
Setting and Design
ISACS-TC (International Survey of Acute Coronary Syn-
dromes in Transitional Countries; ClinicalTrials.gov identified
NCT01218776.) is a large observational registry initiated in
2010. The protocol was described previously.10–14 Briefly,
ISACS-TC is an investigator-driven initiative designed to
include information on risk factors, clinical presentation,
and complications of acute coronary syndromes. The
registry accurately records times to medications and
interventions. ISACS-TC mainly includes hospitals in coun-
tries with an economy in transition. The aim of ISACS-TC is
to provide a large multinational registry of the full spectrum
of patients with acute coronary syndromes to develop and
evaluate survey measures that elicit improved outcomes in
countries embarked on reforming their healthcare systems.
Patients were enrolled from 41 geographically diverse sites.
Of these hospitals, 22 were tertiary healthcare services
providing advanced medical investigation and treatment
including percutaneous coronary intervention (PCI) and/or
cardiac surgery, and 19 were secondary healthcare services
providing intensive care in critical coronary care units (Data
S1). The study was approved by the local research ethics
committee from each hospital. Because patient information
is collected anonymously, institutional review boards waived
the need for individual informed consent. The data
coordinating center was established at the University of
Bologna.
Patients and Procedures
The study population consisted of 8997 eligible patients with
STEMI or new, or presumed new, bundle-branch block
myocardial infarction enrolled between October 2010 to April
2016. Eligibility was defined by diagnostic changes on the
initial 12-lead ECG, presentation, and no contraindications to
reperfusion therapy.15 Patients were defined as having a
contraindication to reperfusion therapy if they presented to
the enrolling sites within the first 12 hours of symptom onset
but were not offered primary PCI or fibrinolysis (Table S1).
Patients who had facilitated and rescue PCI or coronary artery
bypass grafting were excluded from the analysis. Patients with
unknown time of symptom onset were also excluded. Overall,
2975 of 8997 patients were excluded. The fact that 1801 of
8997 patients (20%) were excluded because of unknown time
of symptom onset is consistent with findings from previous
investigations16 (Table S2). The final analysis population had
6022 participants (Figure).
Data Collection and Definitions
The enrolled hospitals periodically uploaded their data to the
central server of the ISACS-TC. Registry data were collected
by the designated physician at the time of clinical assess-
ment. Killip classification at admission was determined by the
attending physician in the emergency department.17 Patients
were asked about the quality of their symptoms. Typical chest
pain was defined as any symptom of chest discomfort
characterized by a sensation or pressure or tightness under
the sternum or chest bone, with pain that may radiate to jaw,
arms, or neck. The variable of atypical chest pain included
both patients with atypical symptoms and those who were
asymptomatic. Chest pain was considered to be atypical when
its distribution was unusual, such as pressure or pain in the
lower chest or upper abdomen or pain or discomfort in one or
both arms, the back, or the stomach. Patients with angina
“equivalents,” such as dyspnea, and fatigue, were defined as
asymptomatic.
Clinical Perspective
What Is New?
• Our analyses indicate that sex differences in outcomes
persist among patients with ST-segment–elevation myocar-
dial infarction and appear to be driven by prehospital delays
in hospital presentation; however, higher 30-day mortality of
women compared with men after ST-segment–elevation
myocardial infarction was confined to times from symptom
onset to presentation >1 hour. Consequently, women
appear to be more vulnerable to prolonged untreated
ischemia.
What Are the Clinical Implications?
• Reducing the time lag between onset of ischemic symptoms
and hospital presentation to ≤1 hour is of the utmost
importance, especially for women.
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Treatment Delays
The estimates of various delays in the initiation of reperfusion
therapy were based on prehospital data registered by the local
hospital provider. Data were then registered in the ISACS-TC
registry. Different delays were classified into 5 categories, and
each was given an operational definition. Time to presentation
(category 1) was the time lag from symptom onset to in-hospital
diagnosis. In the ISACS-TC registry, any patient with symptoms
suggestive of myocardial infarction should have a 12-lead ECG
taken as soon as possible on arrival at the emergency
department. Time to first medical contact (category 2) was
the time lag from symptom onset to the call seeking care, which
included calls to emergency medical services (EMS) or a
general physician’s office. Calls for EMS were registered at the
dispatch center. Data on calls for a general physician’s office
were based on physician self-reports of scheduled calls and
visit times. These estimates were documented when the
registry data were collected. Time from first medical contact to
hospital presentation (category 3) was the time lag from call for
help contacting EMS or a general physician’s office to arrival at
the emergency department. If patients were admitted to a
secondary hospital and then transferred to a tertiary PCI-
capable hospital, time from first medical contact to hospital
presentation included departure from the secondary hospital
and arrival at the PCI center. Self-presenters who reached the
hospital just by walking or using public transportation or
personally operated vehicles were included in the analysis
provided that they had previously contacted their general
physician. Door-to needle (category 4) was the time lag from
arrival at the local emergency department to the beginning of
fibrinolytic therapy. Door-to-balloon (category 5) was the time
lag from arrival at the emergency department of the PCI center
to first balloon inflation during primary PCI.
End Points and Measurements
The primary outcome was the incidence of 30-day all-cause
mortality. The analysis evaluated patient outcomes from
hospital admission through the end of the follow-up period.
The use of medications given at hospital admission was noted,
as well as the use of primary PCI or fibrinolysis. Information
on treatment delays was obtained from review of the medical
records. The rationale for using limit cutoffs of 12, 4, 2, and
1 hour for time to presentation was based on international
guidelines,18,19 targets set by the UK National Service
Framework,20 and previous data regarding infarct develop-
ment in men.21–24 We also studied the likelihood of having
cardiogenic shock (Killip class IV) diagnosed at presentation.
Statistical Analysis
Statistical testing of patient characteristics by sex was
performed with the use of the v2 test for categorical variables
Figure. Flow diagram of patients entered into the study. CABG indicates coronary artery bypass grafting; ISACS-TC, International Survey of Acute
Coronary Syndromes in Transitional Countries; PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction.
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and the Wilcoxon rank sum test for continuous and ordinal
variables. Descriptive statistics using medians with 25th and
75th percentiles for continuous variables and percentages for
discrete variable were generated for baseline characteristics
by these groups. Statistical evaluation was performed using
STATA 11 (StataCorp). All P values were 2-sided and were
considered statistically significant if ≤0.05.
Clinical end point of 30-day all-cause mortality
The clinical end point of 30-day all-cause mortality was
compared between the overall population of men and women
with STEMI using estimates of the odd ratios (OR) and
associated 95% confidence intervals (CIs). Patients were also
stratified into time-delay cohorts for time to presentation: ≤1,
>1 to ≤2, >2 to ≤4, >4 to ≤12, and >12 hours. Fixed
covariates included in the analyses were sex, age, cardiovas-
cular risk factors (history of hypercholesterolemia, history of
diabetes mellitus, history of hypertension, family history
of coronary artery disease, smoking status), clinical history of
ischemic heart disease (prior angina, prior myocardial infarc-
tion [MI], prior PCI, and prior coronary artery bypass grafting),
clinical history of cardiovascular disorders (prior heart failure
and prior stroke), history of chronic kidney disease, and
clinical presentation (systolic blood pressure, heart rate, and
atypical chest pain). Medications and procedures at hospital
admission were included in the analyses as categorical
variables. Statistical adjustments were made for primary PCI,
fibrinolysis, aspirin, clopidogrel, unfractioned heparin, beta
blockers, and angiotensin-converting enzyme inhibitors.
Prehospital delays and cardiogenic shock at hospital
admission
The covariate-adjusted association between prehospital
delays and cardiogenic shock was assessed by multivariate
logistic regression considering all preadmission clinical vari-
ables, specifically sex, age, cardiovascular risk factors, clinical
history of ischemic heart disease, cardiovascular disorders,
and chronic kidney disease.
Missing values and mortality
We had complete data on age, sex, and 30-day mortality.
Some patients had missing data on other variables. We
multiply imputed the missing values of the variables with a
missing rate <10% using STATA software. For the features
with a missing rate >10%, we carried out a Pearson v2
statistical test for independence between those features and
mortality. Only the variables of hypercholesterolemia and
atypical chest pain had missing rates >10% and were found to
be statistically dependent on the end point mortality.
Consequently, we did not dismiss these variables from the
predictive model of mortality, and we kept them as missing.25
Results
From October 2010 through April 2016, a total of 8997 STEMI
patients at 41 sites in 12 countries were enrolled in the
ISACS-TC registry. Of these 8997 patients, 6022 were
included in the current analysis. Figure shows the flow
diagram of patients entered into the study. There were 1372
(22.8%) patients who sought medical attention 12 hours after
symptom onset and did not receive any reperfusion therapy
(primary PCI or fibrinolysis) Table S3).
Sample Characteristics
Baseline characteristics of the patients are shown in Table 1.
The cohort was predominantly male. Women were older and
more often had diabetes mellitus and hypertension but were
less likely to have a history of prior myocardial infarction or to
be smokers. They were given less antithrombotic medication
and fibrinolysis (12.8% versus 14.8% Table 1).
Delays to Hospital Presentation
Despite similar delays in seeking care, women were more likely
to experience longer prehospital delays than men (Table 2).
The median duration of time from symptom onset to in-
hospital diagnosis in women was 270 minutes and in men was
240 minutes. Delay in hospital presentation was mainly
related to the time lag between first medical contact and
hospital presentation. The median differences between women
and men ranged from 20 to 45 minutes. Women had 30 more
minutes from time of symptom onset to hospital presentation.
Of note, no significant differences were observed between
women and men in door-to-balloon and door-to-needle times.
Table 2 summarizes differences in the distributions of men
and women according to the designated time-delay cohorts
after symptom onset. The proportion of patients presenting
>12 hours after the onset of symptoms was greater among
women than men (27.7% versus 21.2%). Patients arriving at the
hospital within 2 hours of symptom onset were more likely to
be male (30.8% versus 24.2%). Similar findings were observed
when using a cut point at 4 hours to separate early from late
care seekers (53.4% versus 47.4%). In multivariable analysis
adjusted for other predictors of mortality, time from symptom
onset to in-hospital diagnosis was independently associated
with mortality in patients presenting to the hospital within
48 hours (OR of 1.02 [95% CI, 1.01–1.03] per 1-hour delay;
Table S4).
Role of EMS and PCI-Capable Hospitals
A variety of factors may be associated with more prolonged
time from first medical contact to hospital presentation in
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women. Among these factors, we analyzed sex differences in
rates of transportation to hospitals by EMS ambulance and in
priority for transport to PCI-capable hospitals. In the overall
study population, 42% of patients turned to the EMS as their
first medical contact (42.9% of men and 40.3% of women).
After adjustment for demographic and clinical factors, women
had similar odds of being transported to the hospital by
ambulance (OR: 0.91; 95% CI, 0.77–1.06; P=0.24). Patients
presenting to a non–PCI-capable hospital and requiring
transfer to a PCI-capable hospital were mostly men (27.4%
versus 24.9%). Similarly, more men than women received
fibrinolysis (14.8% versus 12.8%; Table 1). A reason for these
Table 1. Baseline Characteristics of the Participants
Characteristics
Overall Study
Population
(N=6022) Men (n=4302)
Women
(n=1720) P Value*
Age (y), meanSD 60.911.7 59.311.5 64.811.4 <0.001
Cardiovascular risk factors
Hypercholesterolemia, n/total, % 2041/5262 (38.8) 1458/3771 (38.7) 583/1491 (39.1) 0.76
Diabetes mellitus, n, % 1328 (22.1) 827 (19.2) 501 (29.1) <0.001
Hypertension, n, % 3738 (62.1) 2509 (58.3) 1229 (71.4) <0.001
Current smoker, n, % 2530 (42.0) 2003 (46.6) 527 (30.6) <0.001
Family history of CAD, n, % 1843 (30.6) 1276 (29.7) 567 (32.9) 0.007
Clinical history of ischemic heart disease
Prior angina pectoris, n, % 713 (11.8) 474 (11.1) 239 (13.9) 0.002
Prior myocardial infarction, n, % 736 (12.2) 558 (12.9) 178 (10.3) 0.005
Prior PCI, n, % 833 (13.8) 599 (13.9) 234 (13.6) 0.75
Prior CABG, n, % 57 (0.9) 44 (1.0) 13 (0.8) 0.33
Clinical history of cardiovascular disorders
Prior heart failure, n, % 186 (3.1) 125 (2.9) 61 (3.5) 0.19
Prior stroke, n, % 254 (4.2) 161 (3.7) 93 (5.4) 0.004
Clinical presentation
Atypical chest pain, n/total, % 220/4623 (4.8) 144/3281 (4.4) 76/1342 (5.7) 0.065
Systolic BP at baseline (mm Hg), meanSD 139.924.7 140.124.2 139.626.3 0.49
Heart rate at baseline (bpm), meanSD 80.422.8 80.222.1 81.224.3 0.13
Chronic kidney disease, n, % 266 (4.2) 177 (4.1) 89 (5.2) 0.16
In-hospital acute medications
Aspirin, n, % 5911 (98.2) 4238 (98.5) 1673 (97.3) 0.004
Clopidogrel, n, % 5563 (92.4) 4000 (92.9) 1563 (90.9) 0.01
Unfractioned heparin, n, % 3766 (62.5) 2774 (64.5) 992 (57.7) <0.001
LMWH, n, % 1687 (28.0) 1214 (28.2) 473 (27.5) 0.24
Fondaparinux, n, % 170 (2.8) 121 (2.8) 49 (2.8) 0.25
Beta blockers, n, % 1317 (21.9) 987 (22.9) 330 (19.2) 0.006
ACEIs, n, % 1426 (23.7) 1068 (24.8) 358 (20.8) 0.004
Reperfusion therapy
Primary PCI, n, % 4222 (70.1) 3067 (71.3) 1155 (67.1) 0.002
Fibrinolysis, n, % 860 (14.3) 639 (14.8) 221 (12.8) 0.04
Outcomes
30-Day all-cause mortality, n, % 413 (6.9) 228 (5.3) 185 (10.8) <0.001
ACEI indicates angiotensin-converting enzyme inhibitor; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; LMWH, low-molecular-weight heparins;
PCI, percutaneous coronary intervention.
*P value derived from comparison between men and women.
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findings may be that women presented later and often out of
the fibrinolytic window of 12 hours (21.7% versus 13.8%).
Among patients who required transfer from a non–PCI-
capable to a PCI-capable hospital, women had a median time
from symptom onset to PCI at the final hospital destination of
400 minutes compared with 360 minutes for men (Table S5).
In the model considering only the group of patients
transferred by EMS ambulance directly to a PCI-capable
hospital, women still had a median time to presentation of
210 minutes compared with 180 minutes for men.
Impact of Various Treatment Delays
When all of the baseline clinical variables (fixed covariates)
were assessed simultaneously in multivariable analysis
(Table 3), 6 remained significant predictors of 30-day all cause
mortality: older age, female sex, prior stroke, chronic kidney
disease, and clinical presentation with higher heart rate or
lower systolic blood pressure. The adjusted OR for mortality
associated with female sex did not change when controlling for
medication use at admission (Table S6). Estimates of mortality
in women compared with men were repeated in the time-delay
cohorts for time to hospital presentation (≤1, >1 to ≤2, >2 to
≤4, >4 to ≤12, >12 hours; Table 4). Significant sex difference
was no longer observed for patients having delays in time to
presentation of <2 hours. Of note, similar odds for 30-day
mortality were observed with delays of ≤1 hour (OR: 0.77; 95%
CI, 0.29–2.02). After adjusting for demographic and clinical
covariates, the ORs for 30-day mortality in women were 0.29
(95% CI, 0.13–0.64) for time to presentation ≤1 hour; 0.53
(95% CI, 0.30–0.95) for >1 to ≤2 hours; 0.61 (95% CI, 0.38–
0.97) for>2 to ≤4 hours; and 0.61 (95%CI, 0.40–0.95) for>4 to
≤12 hours. The corresponding values in the overall population
were 0.46 (95% CI, 0.30–0.71), 0.55 (95% CI, 0.39–0.78), 0.59
(95% CI, 0.44–0.81), and 0.54 (95% CI, 0.40–0.72), respec-
tively. We conducted further analyses to assess the robustness
of our results. First, we used the variable of time to presentation
as a covariate rather than to stratify the data by delay cohorts
(Figure S1). A strong and graded relation was noted between
time to presentation and risk of 30-day mortality, with the risk
decreasing at every time decrement of the delay, so that
patients with a time to presentation ≤1 hour had an OR of 0.30
(95% CI, 0.20–0.44) compared with the reference group of
patients with a time to presentation >12 hours. This relation-
ship was stronger for women.We then performed an interaction
test between time to presentation ≤1 hour (reference group)
and delay of ≥12 hours. Results were similar, although risk
differences were attenuated (Table S7). The OR for women
compared with men having 30-day mortality was 1.43 (95% CI,
1.03–1.98) with no significant interaction effect.
Cardiogenic Shock
Information on Killip classification at admission was available
for 4003 patients. Women had higher unadjusted and
adjusted risk of having a diagnosis of cardiogenic shock
(Killip class IV) at hospital admission than men (Table S8).
Comparison of time-delay cohorts revealed that the risk of
Table 2. Delays and Stages of the Process of Treatment
Overall Study
Population (N=6022) Men (n=4302) Women (n=1720) P Value*
Median delays
Time to from first medical
contact (min), median (IQR)
50 (20–180) 50 (20–180) 60 (15–180) 0.60
Time from first medical contact to hospital
presentation (min), median (IQR)
67 (40–130) 60 (40–120) 88 (60–165) 0.001
Time to presentation (min), median (IQR) 240 (120–650) 240 (120–600) 270 (130–776.5) <0.001
Door to needle (min), median (IQR) 27 (15–42) 26 (15–41) 28 (15–43.5) 0.56
Door to balloon (min), median (IQR0 45 (25–80) 45 (27–80) 45 825–75) 0.11
Time-delay cohorts
Time to presentation >12 h, n, % 1372 (22.8) 912 (21.2) 460 (27.7) <0.001
Time to presentation >4 to ≤12 h, n, % 1536 (25.5) 1091 (25.4) 445 (25.9) <0.001
Time to presentation >2 to ≤4 h, n, % 1372 (22.8) 973 (22.6) 399 (23.2) <0.001
Time to presentation >1 to ≤2 h, n, % 1022 (16.9) 779 (18.1) 243 (14.1) <0.001
Time to presentation ≤1 h, n, % 720 (11.9) 547 (12.7) 173 (10.1) <0.001
IQR indicates interquartile range.
*P value derived from comparison between men and women.
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cardiogenic shock was significantly greater for women
compared with men of similar age and similar risk profile
when time to hospital presentation was >4 hours (adjusted
OR: 1.80; 95% CI, 1.04–3.14).
Discussion
The main finding of the current study is that sex differences in
30-day all-cause mortality following STEMI persist and appear
to be driven by delays in presentation to the hospital. In
general, women were more likely to experience longer delays
than men. Increasing time to presentation was associated
with an increasing rate of mortality in both sexes. Notably,
simple time-delay adjustment eliminated the sex difference in
mortality rate for patients with delays from symptom onset to
hospital presentation of ≤1 hour. The present study, there-
fore, not only indicates that women have greater prehospital
delays to presentation after STEMI, and consequently greater
mortality, but also demonstrates a differential effect of sex on
the association between delays and mortality. These findings
raise concerns about treatment and triage strategies used by
first responders and about transfer procedures between
hospitals. These data also suggest that women are more
vulnerable than men to prolonged untreated ischemia.
Previous Studies
Consistent with many studies conducted in diverse clinical
settings, this study found that women with STEMI are at
greater risk of 30-day all-cause mortality compared with men,
despite adjustment for clinical baseline variables.6,26–28 Our
analysis, however, differs from previous reports of outcomes
following STEMI because prior studies have not looked at sex
differences in outcomes adjusted for time from symptom
onset to hospital presentation and subsequent late or no
utilization of cardiac revascularization procedures, and rates
of revascularization are typically and significantly lower in
women compared with men.4,29–33
Sources of Delays
Several studies have documented that delays can occur from
different sources, including patients and providers and the
healthcare system itself.34,35 We demonstrated that women
with suspicion of STEMI have longer times for calling medical
services, longer times to hospital presentation, and ultimately
significantly delayed use of reperfusion therapies. Previous
work has shown that women have longer door-to-balloon
times36 and longer door-to-needle times.37 This was not
observed in the current study, which showed similar
in-hospital times for reperfusion therapy once STEMI was
documented at the emergency department.
Patient-Related Delays
Our data demonstrate that women are more likely than men to
encounter delays between the onset of symptoms and first
medical contact.3,38,39 We do not have data about whether the
problem from the perspective of the women is related to
symptom recognition, symptom interpretation, or decisions
related to care seeking, including the mode of transportation to
the hospital. Women with chest pain often may consider their
symptoms normal and seek help from incorrect sources.3,38,39
Angina in women can manifest as atypical chest pain or
dyspnea.3,38 In our study, the proportion of patients with
atypical presentation of chest pain was higher for women than
for men, but this finding was uncommon for both sexes (6%
versus 4%), and thus cannot entirely explain the large difference
in thedelay in hospital presentationbetweenwomen andmen.40
Delays on the Part of the Healthcare System
Our study found longer delays on the part of the health system
than on the part of patients. Only a minority of patients
Table 3. Multivariate Analysis of Factors Associated With
30-Day All-Cause Mortality
OR 95% CI P Value
Unadjusted 2.15 1.76–2.64 <0.001
Multivariate adjusted
Women 1.58 1.27–1.97 <0.001
Age 1.07 1.05–1.08 <0.001
Hypercholesterolemia 0.99 0.96–1.04 0.95
Diabetes mellitus 1.05 0.99–1.12 0.10
Hypertension 1.01 0.92–1.11 0.80
Current smoker 1.03 0.95–1.11 0.51
Family history of CAD 1.04 0.99–1.08 0.070
Atypical chest pain 1.01 0.98–1.04 0.56
Heart rate at admission
(per 1-SD increment*)
1.38 1.22–1.55 <0.001
Systolic blood pressure
at admission
(per 1-SD increment*)
0.57 0.52–0.63 <0.001
Prior angina pectoris 0.79 0.56–1.11 0.18
Prior myocardial infarction 1.02 0.73–1.44 0.87
Prior PCI/CABG 1.26 0.91–1.73 0.15
Prior heart failure 1.22 0.74–1.97 0.42
Prior stroke 1.99 1.37–2.91 <0.001
Chronic kidney disease 1.36 1.20–1.54 <0.001
*SDs for heart rate and systolic blood pressure are 23 bpm and 25 mm Hg.
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(28.8%) reached the hospital within 2 hours. Delays in
presentation to the hospital (48.3%) mostly ranged between
2 and 12 hours. Women were more likely to experience longer
delays to hospital presentation than men, in keeping with
previous work.41,42 The different twist in this study was that
delay to hospital presentation was mainly related to the time
lag between first medical contact and hospital presentation,
which stimulates concern about the system-related causes.
Provider delays primarily involve lack of early diagnosis and/
or lower priority for ambulance transport to a PCI-capable
hospital. Our data indicate no significant difference among the
rates of women and men using EMS. Similar data on the use of
EMS have been reported in the United States and Swe-
den.43,44 Contrary to expectations, women showed signifi-
cantly higher rates of admission to primary PCI-capable
hospitals; however, prehospital delays were still greater
among women. These findings underscore the need to
improve the management of female patients, even at the
EMS centers, perhaps by improving the use of prehospital
12-lead ECG for early identification of STEMI.45 There is a
need for transfer algorithms, including EMS, non-PCI hospi-
tals/STEMI referring centers, and PCI hospitals/STEMI receiv-
ing centers, to evaluate outcomes and quality improvement
data.46
Delays to Hospital Presentation and Sex
Differences in Mortality
Overall, 30-day mortality was higher for women compared
with their male counterparts in the study population. Although
5.3% of men died within 30 days, the mortality rate for
women was nearly double at 10.8%. Increasing delay in
presentation was associated with an adjusted increase in
30-day mortality for all time cohorts in both women and men;
however, when the sample was subdivided into time cohorts,
no sex difference in mortality was found in the lowest time-
delay group (<1 hour, OR: 0.77; 95% CI, 0.29–2.02), whereas
among patients arriving later, women showed a higher
mortality rate compared with men, ranging from adjusted
ORs of 1.29 to 1.73.
Table 4. Impact of Various Treatment Delays on the Odds of Mortality for Women
OR (95% CI) P Value
Unadjusted
Event rate, %
Model 1: Overall study population adjusted for demographic and clinical factors
30-Day all-cause mortality in all STEMI population 1.58 (1.27–1.97) <0.001 6.9
30-Day all-cause mortality in patients receiving pPCI 1.56 (1.25–1.95) <0.001 4.8
30-Day all-cause mortality in patients receiving fibrinolysis 1.58 (1.27–1.97) <0.001 7.8
Model 2: Time to presentation >12 h (n=1372)
30-Day all-cause mortality in all STEMI population 1.57 (1.09–2.25) 0.015 12.4
Model 3: Time to presentation >4 to ≤12 h (n=1536)
30-Day all-cause mortality in all STEMI population 1.73 (1.09–2.76) 0.020 5.7
30-Day all-cause mortality in patients receiving pPCI 1.71 (1.07–2.73) 0.023 5.1
30-Day all-cause mortality in patients receiving fibrinolysis 1.71 (1.07–2.74) 0.023 9.5
Model 4: Time to presentation >2 to ≤4 h (n=1372)
30-Day all-cause mortality in all STEMI population 1.77 (1.05–2.99) 0.031 5.5
30-Day all-cause mortality in patients receiving pPCI 1.84 (1.08–3.11) 0.023 4.8
30-Day all-cause mortality in patients receiving fibrinolysis 1.84 (1.09–3.11) 0.023 8.7
Model 5: Time to presentation >1 to ≤2 h (n=1022)
30-Day all-cause mortality in all STEMI population 1.29 (0.65–2.58) 0.46 4.9
30-Day all-cause mortality in patients receiving pPCI 1.29 (0.65–2.59) 0.46 4.5
30-Day all-cause mortality in patients receiving fibrinolysis 1.29 (0.65–2.59) 0.46 6.4
Model 6: Time to presentation ≤1 h (n=720)
30-Day all-cause mortality in all STEMI population 0.77 (0.29–2.02) 0.59 4.0
30-Day all-cause mortality in patients receiving pPCI 0.75 (0.28–1.99) 0.57 3.8
30-Day all cause mortality in patients receiving fibrinolysis 0.75 (0.28–1.99) 0.57 4.9
CI indicates confidence interval; OR, odds ratio; pPCI indicates primary percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction.
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Sex Differences in Response to Prolonged
Untreated Ischemia
The mechanism of why a delay of >1 hour is associated with
poorer survival in women compared with men could not be
completely ascertained. Women were significantly more likely
to experience cardiogenic shock in all groups of delay
>4 hours, suggesting that some biological differences
between sexes may contribute to altered myocardial response
to infarction, which also may constitute a possible mechanism
to explain different rates of mortality.47–49
Study Limitations
Some limitations in the current analyses must be noted. First,
our data are observational, and thus some degree of residual
confounding cannot be excluded; however, the effects of
different prehospital delays on mortality cannot be subjected
to randomized assessments. Second, we were unable to
determine whether prehospital characteristics of the patient’s
home and rural location could have played a role in the delays
in hospital presentation and treatment. Although such infor-
mation might have provided useful insights, its absence does
not compromise the actual findings of the study. Third, the
geographical and organizational conditions of the ISACS-TC
registry may not necessarily apply to other countries and
regions.
Conclusions
Our analyses indicate that sex differences in outcomes persist
among STEMI patients and appear to be driven by prehospital
delays in hospital presentation. Higher 30-day mortality
among women compared with men after STEMI is confined
to times from symptom onset to presentation >1 hour.
Reducing the time lag between onset of ischemic symptoms
and hospital presentation is of the utmost importance for
women because they seem to be more vulnerable to
prolonged untreated ischemia. Further investigations may
address the mechanisms that make women more vulnerable.
Disclosures
None.
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ISACS-TC sites:  
Bosnia and Herzegovina: Clinical Center of Banja Luka, Republika Srpska, Banja Luka; 
Clinical Center University of Sarajevo, Sarajevo; Opšta Bolnica:"Sveti Vracevi"; Opšta 
Bolnica, Gradiška; Klinički Centar, Kasindo; Dom Zdravlja “Dr Mladen Stojanovć”, 
Bačka Palanka; Opšta Bolnica “Sveti Apostol Luka”, Doboj; Univesity Clinical Hospital 
Mostar. Croatia: University Hospital Centre of Zagreb, Zagreb; Clinical Hospital 
Merkur, Zagreb; Clinical Hospital Dubrava, Zagreb. Italy: Sapienza-Cuore Grossi Vasi, 
Rome. Kosovo: Clinical Center of Kosovo, Prishtina. Lithuania: Hospital of Lithuanian 
University of Health Sciences, Kaunas. Macedonia: University Clinic of Cardiology, 
Skopje. Hungary: University of Pecs, Medical School, 1st Department of Medicine, 
Division of Cardiology. Moldova: Hospital Center of Cardiology; Institute of 
Cardiology, Chișinău. Montenegro: Clinical Center of Montenegro, Podgorica; General 
Hospital Kotor; Opšta Bolnica Meljine, Herceg Novi; JZU Dom Zdravlja Plav - Interno 
Odjeljenje; General Hospital Pljevlja; Opšta Bolnica Berane; Opšta Bolnica Bijelo Polje; 
Opšta Bolnica Danilo I, Cetinje; PZU OB.MELJINE. Romania: Spitalul Clinic de 
Urgenta, Bucaresti; Spitalul Judetean, Baia Mare. Russian Federation: Institute of 
Therapy and Preventive Medicine in Novosibirsk, Russian Academy of Medical Sciences 
in Novosibirsk. Serbia: University of Belgrade, Clinical Center of Serbia, Belgrade; 
Clinical Hospital Center, Zemun; Zvezdara University Hospital Center; University 
Hospital Medical Center Bezanijska Kosa; Hospital of Valjevo; City Hospital, Mitrovica; 
Clinical Center Kragujevac; General Hospital Cuprija; General Hospital Dr. Djordje 
Joanovic; Cardiology Clinic, Institute for Treatment and Rehabilitation; General Hospital 
Jagodina; KBC Kosovska Mitrovica. 
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Table S1. Baseline characteristics of patients with contraindications to reperfusion therapy 
Characteristics 
Overall 
population 
N=953 
Men 
(N=590) 
Women 
(N=363) 
P-
value† 
     
Age (years), mean±SD 65.8 ± 13.2 62.8 ± 13.4 70.6 ± 11.3 <0.001 
Cardiovascular risk factors     
Hypercholesterolemia, n/total 
(%) 
261/763 (34.2) 159/475 (33.5) 102/288 (35.4) 0.58 
Diabetes, n (%) 261 (27.4) 147 (24.9) 114 (31.4) 0.09 
Hypertension, n (%) 612 (64.2) 349 (59.1) 263 (72.4) <0.001 
Current smoker, n (%) 252 (26.4) 190 (32.2) 62 (17.1) <0.001 
Family history of CAD, n (%) 235 (24.7) 141 (23.9) 94 (25.9) 0.51 
Clinical history of ischemic heart disease     
Prior angina pectoris, n (%)  144 (15.1) 87 (14.7) 57 (15.7) 0.69 
Prior myocardial infarction, n 
(%)  
172 (18.0) 119 (20.2) 53 (14.6) 0.03 
Prior PCI, n (%) 96 (10.1) 65 (11.0) 31 (8.50) 0.21 
Prior CABG, n (%) 30 (3.1) 23 (3.9) 7 (1.9) 0.09 
Clinical history of cardiovascular disorders   
Prior heart failure, n (%) 56 (5.9) 33 (5.6) 23 (6.3) 0.63 
Prior stroke, n (%) 77 (8.1) 45 (7.6) 32 (8.8) 0.51 
3 
 
Clinical presentation     
Atypical chest pain, n/total 
(%) 
106/865 (12.2) 54/536 (10.1) 52/329 (15.8) 0.013 
Systolic BP at baseline 
(mmHg), mean±SD 
136.3 ±29.4 135.8 ± 29.7 136.9 ± 28.8 0.55 
Heart rate at baseline (b.p.m.), 
mean±SD 
83.3 ± 22.9 83.2 ± 23.4 83.5 ± 22.2 0.83 
Chronic kidney disease, n (%) 103 (10.8) 60 (10.2) 463 (0.8) 0.59 
In-hospital acute medications     
Aspirin, n (%) 849 (89.1) 535 (90.7) 314 (86.5) 0.11 
Clopidogrel, n (%) 652 (68.4) 415 (70.3) 237 (65.3) 0.11 
Unfractioned heparin, n (%) 381 (39.4) 241 (40.8) 140 (38.6) 0.37 
LMWH, n (%) 405 (42.5) 252 (42.7) 153 (42.1) 0.33 
Fondaparinux, n (%) 29 (3.1) 19 (3.2) 10 (2.7) 0.36 
Β-blockers, n (%) 171 (17.9) 108 (18.3) 63 (17.4) 0.51 
ACE-inhibitors, n (%) 168 (17.6) 111 (18.8) 57 (15.7) 0.33 
Outcomes     
30-day all-cause mortality, n 
(%) 
162 (17.0) 88 (14.9) 74 (20.4) 0.03 
†P-value derived from comparison between men and women. BP, blood pressure; CAD, coronary 
artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; 
LMWH, Low molecular weight heparins; ACE, angiotensin-converting-enzyme. 
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Table S2. Baseline characteristics of patients with unknown time of symptom onset  
Characteristics 
Overall 
population 
N=1801 
Men 
(N=1231) 
Women 
(N=570) 
P-
value† 
     
Age (years), mean±SD 62.5 ± 12.2 60.3 ± 11.5 67.4 ± 12.2 <0.001 
Cardiovascular risk factors     
Hypercholesterolemia, n/total 
(%) 
642/1431 
(44.9) 
429/972 
(44.1) 
213 /459 
(46.4) 
0.42 
Diabetes, n (%) 457 (25.4) 290 (23.6) 167 (29.3) 0.02 
Hypertension, n (%) 1177 (65.3) 753 (61.2) 424 (74.4) <0.001 
Current smoker, n (%) 728 (40.4) 563 (45.7) 165 (29.9) <0.001 
Family history of CAD, n (%) 576 (31.9) 397 (32.2) 179 (31.4) 0.89 
Clinical history of ischemic heart disease     
Prior angina pectoris, n (%)  417 (23.1) 261 (21.2) 156 (27.4) 0.004 
Prior myocardial infarction, n 
(%)  
186 (10.33) 131 (10.6) 550 (9.6) 0.52 
Prior PCI, n (%) 101 (5.6) 74 (6.0) 27 (4.7) 0.27 
Prior CABG, n (%) 28 (1.55) 23 (1.9) 5 (0.9) 0.11 
Clinical history of cardiovascular disorders 
Prior heart failure, n (%) 111 (6.2) 71 (5.8) 40 (7.0) 0.30 
Prior stroke, n (%) 50 (2.8) 31 (2.5) 19 (3.3) 0.32 
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Clinical presentation     
Atypical chest pain, n/total 
(%) 
93/1691 (5.5) 62 (5.4) 31 (5.7) 0.75 
Systolic BP at baseline 
(mmHg), mean±SD 
136.6 ± 22.0 137.2 ± 20.3 135.5 ± 25.3 0.12 
Heart rate at baseline (b.p.m.), 
mean±SD 
80.5 ± 19.2 80.5 ± 20.0 80.4 ± 17.4 0.87 
Chronic kidney disease, n (%) 98 (5.44) 54 (4.4) 44 (7.7) 0.003 
In-hospital acute medications     
Aspirin, n (%) 1695 (94.1) 1164 (94.6) 531 (93.2) 0.42 
Clopidogrel, n (%) 1610 (89.4) 1099 (89.3) 511 (89.6) 0.95 
Unfractioned heparin, n (%) 658 (36.5) 442 (35.9) 216 (37.9) 0.70 
LMWH, n (%) 1,037 (57.6) 710 (57.7) 327 (57.4) 0.95 
Fondaparinux, n (%) 50 (2.8) 34 (2.8) 16 (2.8) 0.96 
Β-blockers, n (%) 968 (53.7) 681 (55.3) 287 (50.3) 0.14 
ACE-inhibitors, n (%) 973 (54.0) 674 (54.7) 299 (52.5) 0.63 
Reperfusion therapy     
Primary PCI, n (%) 1243 (69.0) 878 (71.3) 365 (64.0) 0.001 
Fibrinolysis, n (%) 207 (11.5) 143 (11.6) 64 (11.2) 0.79 
Outcomes     
30-day all-cause mortality, n 
(%) 
97 (5.4) 47 (3.8) 50 (8.8) <0.001 
†P-value derived from comparison between men and women. BP, blood pressure; CAD, 
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coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass graft; LMWH, Low molecular weight heparins; ACE, angiotensin-converting-enzyme. 
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Table S3. Baseline characteristics of patients presenting within and after 12 hours from 
symptom onset 
Characteristics 
Patients within 
12 hours 
(N=4650) 
Patients after 
12 hours 
(N=1372) 
P-value 
    
Age (years), mean±SD 60.0 ± 11.4 63.9 ± 12.3 <0.001 
Women  1260 (27.1) 460 (33.5) <0.001 
Cardiovascular risk factors    
Hypercholesterolemia, n/total 
(%) 
1649/4110 
(40.1) 
392/1152 (34.0) <0.001 
Diabetes, n (%) 959 (20.6) 369 (26.9) <0.001 
Hypertension, n (%) 2879 (61.9) 859 (62.6) 0.42 
Current smoker, n (%) 2118 (45.5) 412 (30.0) <0.001 
Family history of CAD, n (%) 1345 (28.9) 498 (36.6) <0.001 
Clinical history of ischemic heart disease    
Prior angina pectoris, n (%)  519 (11.1) 194 (14.1) 0.003 
Prior myocardial infarction, n 
(%)  
546 (11.7) 190 (13.8) 0.036 
Prior PCI, n (%) 640 (13.8) 193 (14.1) 0.77 
Prior CABG, n (%) 37 (0.8) 20 (1.5) 0.026 
Clinical history of cardiovascular disorders 
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Prior heart failure, n (%) 121 (2.6) 65 (4.7) <0.001 
Prior stroke, n (%) 172 (3.7) 82 (5.9) <0.001 
Clinical presentation    
Atypical chest pain, n/total (%) 90/3390 (2.6) 130/1233 (10.5) <0.001 
Systolic BP at baseline (mmHg), 
mean±SD 
140.9 ± 24.6 136.5 ± 26.9 <0.001 
Heart rate at baseline (b.p.m.), 
mean±SD 
80.0 ± 19.4 81.8 ± 31.6 0.01 
Chronic kidney disease, n (%) 145 (3.1) 121 (8.8) <0.001 
In-hospital acute medications    
Aspirin, n (%) 4598 (98.9) 1313 (95.7) <0.001 
Clopidogrel, n (%) 4417 (94.9) 1146 (83.5) <0.001 
Unfractioned heparin, n (%) 3149 (67.7) 617 (44.9) <0.001 
LMWH, n (%) 1235 (26.6) 452 (32.9) <0.001 
Fondaparinux, n (%) 120 (2.6) 50 (3.6) 0.08 
Β-blockers, n (%) 1100 (23.7) 217 (15.8) <0.001 
ACE-inhibitors, n (%) 1204 (25.9) 222 (16.2) <0.001 
BP, blood pressure; CAD, coronary artery disease; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass graft; LMWH, Low molecular weight 
heparins; ACE, angiotensin-converting-enzyme. 
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Table S4. Multivariate analysis of factors associated with 30-day all-cause mortality in 
patients presenting to hospital within 48 hours 
 
OR 95%CI 
P-
value 
Women  1.61 1.27-2.05 <0.001 
Age  1.06 1.05-1.07 <0.001 
Hypercholesterolemia  0.99 0.94-1.03 0.70 
Diabetes 1.07 0.99-1.14 0.052 
Hypertension 1.02 0.92-1.12 0.75 
Current smoker 1.05 0.97-1.14 0.24 
Family history of CAD 1.06 1.01-1.11 0.012 
Atypical chest pain 1.03 0.99-1.06 0.13 
Heart rate at admission (per 1-SD 
increment*) 
1.38 1.21-1.57 <0.001 
Systolic blood pressure at admission (per 1-
SD increment*) 
0.57 0.51-0.63 <0.001 
Prior angina pectoris  0.85 0.59-1.23 0.39 
Prior myocardial infarction  1.07 0.74-1.54 0.69 
Prior PCI/CABG 1.51 1.08-2.13 0.016 
Prior heart failure 1.20 0.71-2.02 0.48 
Prior stroke 1.99 1.32-3.00 0.001 
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Chronic kidney disease 1.35 1.18-1.53 <0.001 
Time to presentation, per 1-hours increased 1.02 1.01-1.03 0.001 
*SDs for heart rate and systolic blood pressure are 23 b.p.m. and 25 mmHg. 
CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary 
artery bypass graft. 
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Table S5. Comparison of pre-hospital delays in patients who required and did not require transfer to a PCI 
capable hospital 
 
Men Women P-value 
Median delays in patients who required transfer from a PCI non capable to a PCI capable hospital 
Time from first medical contact to hospital 
presentation (min), median (IQR) 
150 (105-285) 167.5 (110-232.5) 0.95 
Time to presentation (min), median (IQR) 360 (180-1076) 400 (205-1025) 0.50 
Median delays in patients transferred by EMS ambulance directly to a PCI capable hospital 
Time from first medical contact to hospital 
presentation (min), median (IQR) 
45.5 (35-70) 70 (44-106.5) 0.001 
Time to presentation (min), median (IQR) 180 (95-430) 210 (120-725) 0.028 
EMS,  emergency medical services; IQR, interquartile range; PCI, percutaneous coronary intervention  
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Table S6. Categorical variables: impact of various medications on the odds of mortality 
for women. 
 OR (95% CI) P value 
Model 1: Overall study population adjusted for demographic and clinical factors 
30-day all-cause mortality 1.58 (1.27-1.97) <0.001 
Model 2: Model 1 including aspirin 
30-day all-cause mortality 1.57 (1.26-1.96) <0.001 
Model 3: Model 1 including aspirin and/or clopidogrel 
30-day all-cause mortality 1.57 (1.26-1.96) <0.001 
Model 4: Model 1 including unfractioned heparin 
30-day all-cause mortality 1.58 (1.27-1.97) <0.001 
Model 5: Model 1 including β blockers 
30-day all-cause mortality 1.57 (1.26-1.95) <0.001 
Model 6: Model 1 including ACE inhibitors 
30-day all-cause mortality 1.57 (1.26-1.95) <0.001 
ACE, angiotensin-converting-enzyme. 
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Table S7. Interaction test between time to presentation of one hour or less (reference group) and delay 
of 12 hours or more 
 OR 95%CI P-value 
Women  1.43 1.03-1.98 0.032 
Delay of 12 hours or more 2.20 1.43-3.42 <0.001 
Age  1.06 1.05-1.08 <0.001 
Hypercholesterolemia  1.02 0.96-1.07 0.43 
Diabetes 0.98 0.90-1.07 0.70 
Hypertension 0.97 0.82-1.16 0.78 
Current smoker 0.96 0.85-1.09 0.56 
Family history of CAD 0.99 0.93-1.07 0.92 
Atypical chest pain 1.02 0.96-1.08 0.45 
Heart rate at admission  (per 1-SD increment*) 1.37 1.14-1.65 0.001 
Systolic blood pressure at admission (per 1-SD increment*) 0.59 0.51-0.68 <0.001 
Prior angina pectoris  0.79 0.49-1.29 0.35 
Prior myocardial infarction  1.03 0.64-1.66 0.89 
Prior PCI/CABG 1.12 0.68-1.84 0.66 
Prior heart failure 0.81 0.39-1.67 0.56 
Prior stroke 1.76 1.02-3.04 0.043 
Chronic kidney disease 1.54 1.22-1.93 <0.001 
*SDs for heart rate and systolic blood pressure are 23 b.p.m. and 25 mmHg. 
CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass graft. 
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Table S8. Cardiogenic shock across the designated time delay cohorts. Rates are stratified by sex: women versus men.  
 Cardiogenic shock rates, n (%) Unadjusted  Adjusted*  
 Men 
(N=2820) 
Women 
(N=1183) 
P-value 
OR (95% CI) P-value OR (95% CI) P-value 
Overall study population, 145(5.1) 102(8.6) <0.001 1.74(1.33-2.26) <0.001 1.56(1.18-2.05) 0.001 
Time to presentation > 12 hours 46(6.2) 42(11.2) 0.004 1.89(1.22-2.93) 0.004 1.68(1.06-2.66) 0.026 
Time to presentation > 4 to  12  hours 37(5.9) 27(10.3) 0.023 1.81(1.07-3.04) 0.025 1.80(1.04-3.14) 0.037 
Time to presentation > 2 to  4 hours 26(4.2) 17(6.4) 0.16 1.55(0.82-2.91) 0.17 1.41(0.74-2.69) 0.30 
Time to presentation > 1 to  2  hours 21(4.4) 10(6.2) 0.35 1.44(0.66-3.12) 0.35 1.22(0.55-2.73) 0.62 
Time to presentation ≤ 1 hour 15(4.0) 6(5.0) 0.64 1.26(0.48-3.31) 0.64 1.21(0.45-3.28) 0.70 
*Adjusted for demographic and clinical factors 
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Figure S1. Odds of 30-day mortality according to time to presentation in overall 
population (panel a) and in women (panel b); reference group: patients with time to 
presentation of more than 12 hours. CI: confidence intervals  
 
 
 
